• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options on June 22, 2026, acquiring 9,500 common shares.
• Rothblatt sold 9,500 shares the same day at weighted average prices ranging from $534.09 to $539.9.
• Directly held common shares stood at 40,513 following the transactions.
• Directly held stock options totaled 144,218 following the exercises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000083), on June 24, 2026, and is solely responsible for the information contained therein.